Products have NOT been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease
REDEFINE 1 Results (Phase 3) The landmark trial randomized 3,417 adults to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo for 68 weeks (Aronne et al., 2025): The combination significantly outperformed either component alone
The trial met its co-primary endpoints, demonstrating that up to 97% of patients taking the China-developed drug achieved at least 5% weight loss, according to Regeneron's press release
(Kaunas.) 57 , 928 (2021)
The comparison between retatrutide and semaglutide makes this distinction clear in the clinical data
Small handful of nuts as snack